A Fizzy Tablet Might One Day Replace a GLP-1 Shot
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
A small company in Paris just won a US patent for a fizzy tablet meant to carry GLP-1 medicine through your stomach so you could swallow it instead of injecting it. While this is very far from being available to you at the pharmacy counter, it’s a new option being explored. It has not been tested in people yet, and there's no medicine you can ask for. Let’s look at what this news means, and why you shouldn’t get too excited about it in the news (yet).
Who This Helps
This is for you if you saw a headline about a GLP-1 pill and wondered whether your shots are about to end. It's also for you if you just like knowing how this stuff works. If the words are new to you, our simple guide to GLP-1 terms is a good place to start.
Why GLP-1 medicine is usually a shot
Most GLP-1 medicines are peptides. A peptide is a short chain of building blocks called amino acids. Think of a string of beads.
Your gut is built to break those strings apart. That's how you digest a steak. Your stomach and intestines are full of enzymes, which act like tiny scissors that cut chains of amino acids into pieces. A peptide medicine swallowed as a normal pill would get cut up before it ever did anything.
There's a second problem. Even the pieces that survive are fairly big and don't cross the gut wall into your blood easily. So a shot skips the whole trip.
There are already peptides you can take in pill form that do work, but the way they are delivered is the secret to bypassing your digestive system so you receive the medication to your bloodstream.
Rybelsus is semaglutide in tablet form. Its label says only about 0.4% to 2% of the dose reaches the bloodstream, depending on the version (Rybelsus prescribing information). The rest is lost. To get even that much, it uses a helper ingredient and comes with strict rules: take it on an empty stomach, with no more than 4 ounces of plain water, then wait at least 30 minutes before food, other drinks, or other pills.
Break the rules and you get less medicine. That's the tradeoff people live with today, though other oral GLP-1s (Foundayo) have worked out a way around this.
What the fizzy tablet is meant to do
The company is BioLife and it calls the technology OralMatrix. Its founder, Dr Farid Bennis, is the inventor, and the company is based in Paris (Drug Target Review). Note that this is not the same company as the US firm BioLife Solutions, which does something unrelated.
The tablet dissolves and fizzes, the same way an antacid tablet fizzes in a glass of water. That fizzing releases gas and changes the conditions right around the medicine. The company describes it as creating a gastric buffer, meaning a protected pocket in the stomach that shields the peptide on its way through and helps it get absorbed.
That's the idea. Whether it works well enough in a human body is the open question, and is sure to be the next thing the company works to prove (though they won’t start with humans just yet).
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
What the patent means, and what it doesn't
A patent is a legal document. It says the government agrees you invented something and gives you the right to stop others from copying it. It is not a test result, and it isn't permission to sell a medicine. Those come from a completely different process.
- What was granted: US Patent 12,667,605 B2, covering the delivery technology across six GLP-1 drugs including semaglutide, liraglutide, dulaglutide and exenatide, with protection running into 2042 (Drug Target Review).
- What the company reports: preclinical studies showing measurable semaglutide in the bloodstream after swallowing it. Preclinical means before any testing in people, usually in a lab or in animals.
- What is missing: no human trial of this technology is registered, and the preclinical results have not been published in a scientific journal for others to check. Everything known about the results comes from the company.
The company says this plainly in its own announcement: "The technology is in development and is not approved for the treatment of any disease" (company announcement).
For a sense of odds, industry figures put the chance of a drug that has already reached the first stage of human testing eventually getting approved at roughly 1 in 10 (Biotechnology Innovation Organization). This one hasn't reached human testing at all. Most ideas at this stage don't become medicines, and the ones that do usually take many years.
Why it would matter if it worked
Three reasons, and they're all about getting medicine to more people.
- Making pills is easier than making shots. Injectable medicine has to be made sterile and filled into pens in special facilities. Tablets can be made on ordinary equipment.
- No refrigerator. Injectable GLP-1 pens need cold storage before use. Tablets sit in a cupboard, which matters for shipping and for anyone without reliable refrigeration.
- Some people won't inject. For them a pill isn't a convenience, it's the difference between treatment and none.
There's already a pill that sidesteps this problem in a different way. Foundayo, approved in April 2026, isn't a peptide at all. It's a small molecule, meaning a much smaller and tougher chemical that survives the gut on its own. Lilly describes it as the only GLP-1 pill for weight loss "that can be taken any time of the day without restrictions on food and water intake" (Eli Lilly). So the fizzy tablet isn't the only route to a pill. It's one attempt at a specific hard problem, which is swallowing a peptide.
Final Takeaway
This is a genuinely neat piece of science and a very early one. A patent means someone has staked a claim on an idea, not that the idea has been proven or that a product is coming. If you're on a GLP-1 today, nothing about your treatment changes because of this. If you're curious about where the field is heading, it's a fair signal that plenty of people are working on making these medicines easier to take. Keep an eye on it, and don't hold your breath. The interesting part will be the first human results, whenever those arrive.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Can I get this fizzy GLP-1 tablet?
No. It is not an approved medicine and has not been tested in people. The company that owns the patent says the technology is in development and is not approved to treat any disease.
Why can't GLP-1 medicine just be made into a normal pill?
Most GLP-1 medicines are peptides, which are short chains of amino acids. Your digestive system is designed to chop chains like that into pieces, and the pieces are too big to cross into your blood easily. A shot goes around the problem entirely.
Isn't there already a GLP-1 pill?
Yes, a few. Rybelsus is a semaglutide tablet for type 2 diabetes, there is now a semaglutide tablet for weight management, and Foundayo is a different kind of molecule taken as a daily pill. The semaglutide tablets come with strict empty-stomach timing rules. Foundayo does not, because it is not a peptide.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Sources
Keep Reading
Oral GLP-1s are taking real market share. See the weight loss numbers side by side and where a pill or a shot genuinely fits better.
Learn what orforglipron is, how this daily oral GLP-1 works, where the research stands now, and what to watch for as it moves toward FDA review.
Two GLP-1 pills are now FDA approved, with more coming. See how oral options could change access, what they cost, and how they compare to shots.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.